Business
Halberd, Corp. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
Halberd, Corp. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases.
About this update from Halberd Corp.
[{"type":"text","content":"Jackson Center, Pennsylvania--(Newsfile Corp. - January 13, 2022) - Halberd, Corp. (OTC PINK: HALB) (\"HALB\" or the \"Company\"), an innovative biotech company focused on developing treatments for difficult-to-cure debilitating diseases, today announces that they have been able to successfully eliminate Beta Amyloid and Interleukin-4 (IL-4) from synthetic cerebral spinal fluid (CSF) in its latest in-vitro laboratory testing. The Company's latest testing accomplishments support its long-standing goal of successfully eradicating all of the top ten target antigens from a static sampling of CSF, thereby permitting control of these target antigens to the prescribed homeostasis level under physician care. Our progress is illustrated in the table below linked to neurodegenerative diseases which have remained virtually untreated over the centuries.Top Ten Neurological Target AntigensProof of Eradication from CSF ResultsTop Ten Neurological Pathogens and Target AntigensProof of Eradication from CSF ResultsAssociated Antigens (Top 10)PTSD/CTENeurodegenerative Diseases*Phosphorylated TauCompletedCompletedIL-6CompletedCompletedTNF-aCompletedCompletedIL-1N/ACompletedIL-12N/ACompletedIL-2N/ACompletedBeta AmyloidN/ACompletedIL-4N/ACompletedTauN/A1Q22Glutamate1Q221Q22N/A - indicates antigen is not associated with specified condition.* Includes Alzheimer's, Parkinson's, Epilepsy & Lou Gehrig's Disease.N/A - indicates antigen is not associated with listed condition** - Includes Alzheimer's, Parkinson's, Epilepsy, and ALSDr. Mitchell S. Felder, HALB's Chief Technology Officer and a board-certified attending neurologist stated, \"Beta-Amyloid is widely recognized to be a major factor of Alzheimer's Disease. Halberd's unique ability to eradicate Beta-Amyloid, coupled with its eradication of IL-4 and its previous elimination of TNF-Alpha, Phosphorylated-Tau, other target antigens, and inflammatory cytokines from CSF, leads the Company to believe it has achieved unparalleled progress toward slowing or preventing the onset of Alzheimer's Disease and other neurodegenerative diseases, such as Epilepsy, Lou Gehrig's Disease (ALS), PTSD, Traumatic Brain Injury, and Chronic Traumatic Encephalopathy. Although comparative, competitive data has been difficult to obtain, we believe that this is a truly spectacular result in comparison to any other competit...